biotech
Shares of Annovis Bio Inc (NYSE: ANVS) more than doubled on Tuesday after the biotech firm reported positive late-stage data for buntanetap. Buntanetap is the candidate treatment of ANVS for Parkinson’s disease. At the time of writing, Annovis stock is trading at $10.50 – still down some 45% versus the start of 2024. What does the data mean for Annovis stock?Buntanetap was shown to be effective in improving motor and nonmotor activities in a Phase 3 trial. It helped patients of Parkinson’s with overall cognitive function as well. Maria Maccecchini – the chief executive of Annovis Bio said in a...
Invezz
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it matter for Humacyte stock?The Acellular Tissue Engineering Vessel of the company based out of North Carolina, United States caters to patients with advanced peripheral artery disease. ATEV is implantable and is used in vascular replacement and repair. Dr. Cindy Cao – the chief regulatory officer of Humacyte said in a press release today: We are exc...
Invezz
Cassava Sciences (NASDAQ: SAVA) stock price has become a fallen angel. Once a high popular stock, it has crashed by over 45% this year and by more than 90% from its all-time high, giving it a market cap of over $530 million. At its peak, the company had a valuation of over $7.4 billion. Fall from grace continuesCassava Sciences, a leading company in Alzheimer’s research, was one of the hottest companies among traders. Its popularity soared in 2021 as most investors focused on Alzheimer after the FDA approved Biogen’s aducanumab, which it started selling at $26,500 per year. Recently, however, ...
Invezz
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) opened more than 30% up on Monday after reporting promising results from a late-stage trial of its heart drug. Shares of the biopharmaceutical company are now trading at a year-to-date high of $220. Why is it significant for Alnylam Pharmaceuticals stock?Vutrisiran demonstrated significant efficacy in reducing mortality and cardiovascular complications in the aforementioned study. It’s a drug that targets transthyretin amyloidosis with cardiomyopathy – a condition that stiffens the heart and impairs blood pumping. Pushkal Garg – the chief medical offi...
Invezz
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing. Alimera Sciences stock valued at a 75% premiumANI Pharmaceuticals is willing to pay $5.50 in cash for each share of Alimera Sciences. It has also agreed to 50 cents a share of additional payout provided that the acquiree hits certain revenue targets in 2026 and 2027. Nikhil Lalwani – the chief executive of $ANIP said in a press release on Monday: We believ...
Invezz
Zealand Pharma (CPH: ZEAL) rallied more than 20% this morning after reporting positive results from an early stage trial of its new weight loss treatment. The biotech firm is now trading at an all-time high. Why is it significant for Zealand Pharma stock?Petrelintide – a long-acting amylin analog of Zealand Pharma showed significant efficacy in a 16-week trial, as per its press release on Friday. Participants receiving high doses successfully lowered their body weight by 8.6% versus only 1.7% observed in the placebo group. Only one participant out of a total of 48 had to withdraw from the stud...
Invezz
Sarepta Therapeutics Inc (NASDAQ: SRPT) rallied a whopping 40% in extended hours today following a key announcement from the U.S. Food and Drug Administration regarding Elevidys. Elevidys is the company’s treatment for Duchenne muscular dystrophy. Why is it significant for Sarepta Therapeutics stock?The FDA granted accelerated approval for a label expansion of “delandistrogene moxeparvovec” to include non-ambulatory patients on Thursday. The decision is significant for individuals with DMD who have lost the ability to walk. Jerry Mendell – the co-inventor of Elevidys said in a press release%2C...
Invezz
Longeveron Inc (NASDAQ: LGVN) rallied another 50% on Thursday as investors continued to celebrate the positive update of its Lomecel-B study. Why is it significant for Longeveron stock?The biotech firm reported encouraging investigator data from the said Phase 2 trial on Tuesday. Lomecel-B is its candidate treatment for hypoplastic left heart syndrome (HLHS). Note that the ELPIS II study is still ongoing. Ram Kumar – the principal investigator of that clinical trial said in a press release today: Lomecel-B clinical data is highly encouraging and suggests it has the potential to be a new, addit...
Invezz
Lodi (United States) (AFP) - It may look like an innocent green plant, but its name evokes something far closer to a robot or interstellar rocket. Neo Px is a bioengineered plant capable of purifying indoor air at an unprecedented scale, the first in a potentially long line of such super-powered organisms. "It's the equivalent of up to 30 regular houseplants in terms of air purification," said Lionel Mora, co-founder of startup Neoplants. "It will not only capture, but also remove and recycle, some of the most harmful pollutants you can find indoors." Five years ago, the entrepreneur met Patr...
AFP
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn’t been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company. GT Biopharma stock trading volume today$GTBP did not publish a press release or file with the Securities & Exchange Commission on Monday. None of the Wall Street analysts issued a bullish note on it either. Still, more than 20 million shares of the Nasdaq-listed firm have exchanged hands today as of writing. The daily trading volume is up massively from about 10,000 only on average. The massive rally ...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら